MedTrace Logo

Adult Attention Deficit Hyperactivity Disorder

NCT01692782 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 341

Last updated 2015-01-12

Study results available
· View outcomes & findings →

Summary

A Phase 2 study of SEP-225289 in adults with attention deficit hyperactivity disorder (ADHD).

Conditions

  • Adult Attention Deficit Hyperactivity Disorder

Interventions

DRUG

SEP-225289

SEP-225289 4mg once daily

DRUG

SEP-225289

SEP-225289 8mg once daily

DRUG

Placebo

Placebo once daily

Sponsors & Collaborators

  • Sumitomo Pharma America, Inc.

    lead INDUSTRY

Principal Investigators

  • CNS Medical Director, MD · Sumitomo Pharma America, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-12-31
Primary Completion
2013-11-30
Completion
2013-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01692782 on ClinicalTrials.gov